27 results on '"De Pas, T."'
Search Results
2. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
3. Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)
4. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
5. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
6. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
7. Erratum to “Lung cancer” [Crit. Rev. Oncol./Hematol. 27 (February (2)) (1998) 133–134]
8. Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment
9. 4 Oral - Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
10. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
11. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
12. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer
13. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
14. Gemcitabine-induced systemic capillary leak syndrome
15. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
16. An Individual Patient Data Meta-Analysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small Cell Lung Cancer: Metastatic Non-Small Cell Lung Cancer
17. An Individual Patient Data Meta-analysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small Cell Lung Cancer
18. 1300P - Buparlisib (Bkm120) in Patients with Pi3K Pathway-Activated, Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Basalt-1 Study
19. 1293P - Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study
20. 1295P - Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1
21. 1173O - Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
22. Reply to the article “Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity” by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543–1550): … and in humans?
23. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary
24. Chemotherapy followed by three-times daily hyperfractionated accelerated radiotherapy in stage IIIa (PN2)/IIIb non small cell lung cancer
25. Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma
26. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?
27. 29 P - Gemcitabine: an active well tolerated drug for advanced non small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.